# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&...
RBC Capital analyst Gregory Renza reiterates BELLUS Health (NASDAQ:BLU) with a Sector Perform and maintains $14.75 price tar...
BELLUS Health (NASDAQ:BLU) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18...
RBC Capital analyst Gregory Renza downgrades BELLUS Health (NASDAQ:BLU) from Outperform to Sector Perform and lowers the pri...
Jefferies analyst Suji Jeong downgrades BELLUS Health (NASDAQ:BLU) from Buy to Hold and lowers the price target from $21 to ...